Federal Register / Vol. 82, No. 196 / Thursday, October 12, 2017 / Notices 47527 

DATES: The meeting will be held on 

November 30, 2017, 9:00 a.m. to 5:00 

p.m., EST and December 1, 2017 9:00 

a.m. to 1:00 p.m., EST. 

ADDRESSES: CDC Chamblee Campus 

4770 Buford Highway, Building 106, 

Room 1B, Atlanta, GA 30341. The webconference access for November 30, 

2017 is https://

ondieh.adobeconnect.com/bccedcac/. 

The web-conference access for 

December 1, 2017 is https://ond

ieh.adobeconnect.com/bccedcac2/. 

FOR FURTHER INFORMATION CONTACT: 

Jameka Reese Blackmon, MBA,CMP, 

Designated Federal Officer, National 

Center for Chronic Disease Prevention 

and Health Promotion, CDC, 4770 

Buford Highway NE., Mailstop F76, 

Atlanta, Georgia, 30341–3717, 

Telephone (770) 488–4740; grz4@

cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The committee is charged 

with advising the Secretary, Department 

of Health and Human Services, and the 

Director, CDC, regarding the early 

detection and control of breast and 

cervical cancer. The committee makes 

recommendations regarding national 

program goals and objectives; 

implementation strategies; and program 

priorities including surveillance, 

epidemiologic investigations, education 

and training, information dissemination, 

professional interactions and 

collaborations, and policy. 

Matters To Be Considered: The agenda 

will include discussions on expanded 

National Breast and Cervical Cancer 

Early Detection Program (NBCCEDP) 

strategies to increase breast and cervical 

cancer screening, review of success with 

implementing evidence-based 

interventions in health systems in the 

Colorectal Cancer Control Program and 

expanding evaluation to measure impact 

and sustainability of population based 

activities. Agenda items are subject to 

change as priorities dictate. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both the 

Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Claudette Grant, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. 2017–22059 Filed 10–11–17; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Submission for OMB Review; 

Comment Request 

Title: Information Comparison With 

Insurance Data. 

OMB No.: 0970–0342. 

Description: The Deficit Reduction 

Act of 2005 amended Section 452 of the 

Social Security Act (the Act) to 

authorize the Secretary, through the 

Federal Parent Locator Service (FPLS), 

to conduct comparisons of information 

concerning individuals owing past-due 

child support with information 

maintained by insurers (or their agents) 

concerning insurance claims, 

settlements, awards, and payments. 42 

U.S.C. 652(m)(1). 

An insurer may choose to participate 

in the data comparison using one of the 

following methods: 

• An insurer submits information 

concerning claims, settlements, awards, 

and payments to the federal Office of 

Child Support and Enforcement (OCSE). 

OCSE compares the information with 

parents who owe past-due support. 

• OCSE sends a file containing 

information about parents who owe 

past-due support to the insurer, or their 

agent to compare with their claims, 

settlements, awards, and payments. The 

insurer or their agent sends the matches 

to OCSE. 

On a daily basis, OCSE sends the 

results of the comparison in the 

Insurance Match Response Record to 

child support agencies responsible for 

collecting past-due support. Child 

support agencies use the matches to 

collect past-due support from the 

insurance proceeds. 

The information collection activities 

pertaining to the information 

comparison with insurance data are 

authorized by: 

(1) 42 U.S.C. 652(a)(9) which requires 

the federal Office of Child Support 

Enforcement (OCSE) to operate the 

FPLS established by 42 U.S.C. 653(a)(1); 

and 

(2) 42 U.S.C. 652(m) which authorizes 

OCSE, through the FPLS, to compare 

information concerning individuals 

owing past-due support with 

information maintained by insurers (or 

their agents) concerning insurance 

claims, settlements, awards, and 

payments, and to furnish information 

resulting from the data matches to the 

state child support agencies responsible 

for collecting child support from the 

individuals. 

Respondents: Insurers or their agents, 

including the U.S. Department of Labor 

and state agencies administering 

workers’ compensation programs, and 

the Insurance Services Office (ISO). 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden hours 

per response 

Total burden 

hours 

Insurance Match File: Monthly Reporting Electronically ................................. 22 12 0.083 22 

Insurance Match File: Weekly Reporting Electronically .................................. 7 52 0.083 30 

Insurance Match File: Daily Reporting Electronically ...................................... 2 251 0.083 42 

Match File: Daily Reporting Manually .............................................................. 80 251 0.1 2,008 

Total .......................................................................................................... ........................ ........................ ........................ 2,102 

Estimated Total Annual Burden 

Hours: 2,102 hours. 

Additional Information: Copies of the 

proposed collection may be obtained by 

writing to the Administration for 

Children and Families, Office of 

Planning, Research and Evaluation, 330 

C Street SW., Washington, DC 20201. 

Attention Reports Clearance Officer. All 

requests should be identified by the title 

of the information collection. Email 

address: infocollection@acf.hhs.gov. 

OMB Comment: OMB is required to 

make a decision concerning the 

collection of information between 30 

and 60 days after publication of this 

document in the Federal Register. 

Therefore, a comment is best assured of 

having its full effect if OMB receives it 

within 30 days of publication. Written 

comments and recommendations for the 


asabaliauskas on DSKBBXCHB2PROD with NOTICES
47528 Federal Register / Vol. 82, No. 196 / Thursday, October 12, 2017 / Notices 

proposed information collection should 

be sent directly to the following: Office 

of Management and Budget, Paperwork 

Reduction Project, Email: OIRA_

SUBMISSION@OMB.EOP.GOV, Attn: 

Desk Officer for the Administration for 

Children and Families. 

Mary Jones, 

Reports Clearance Officer. 

[FR Doc. 2017–21960 Filed 10–11–17; 8:45 am] 

BILLING CODE 4184–41–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2017–N–5568] 

Prescription Drug User Fee Act of 

2017; Electronic Submissions and Data 

Standards; Public Meeting; Request 

for Comments 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of public meeting. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) is 

announcing the following public 

meeting entitled ‘‘Prescription Drug 

User Fee Act of 2017; Electronic 

Submissions and Data Standards.’’ The 

topics to be discussed will include the 

current status of electronic submissions 

and data standards initiatives to 

improve the predictability and 

consistency of the electronic 

submissions process in support of the 

human drug review program. FDA is 

seeking input from a variety of 

stakeholders—industry, academia, 

patient advocates, professional societies 

and other interested parties—as it 

fulfills its commitment under the 

Prescription Drug User Fee Act of 2017 

(PDUFA) to hold annual public 

meetings to seek stakeholder input 

related to enhancing the transparency 

and accountability of the electronic 

submission and data standards 

activities. FDA will use the information 

from the public meeting to inform the 

development of the FDA Information 

Technology (FDA IT) Strategic Plan and 

electronic submissions gateway target 

timeframes. 

DATES: The public meeting will be held 

March 21, 2018, from 9 a.m. to 4 p.m. 

Submit either electronic or written 

comments regarding this public meeting 

prior to the meeting through April 18, 

2018. See the SUPPLEMENTARY

INFORMATION section for registration date 

and information. 

ADDRESSES: The public meeting will be 

held at the FDA White Oak Campus, 

10903 New Hampshire Ave., Bldg. 31 

Conference Center, the Great Room (Rm. 

1503, Section A), Silver Spring, MD 

20993–0002. Entrance for the public 

meeting participants (non-FDA 

employees) is through Building 1, where 

routine security check procedures will 

be performed. For parking and security 

information, please refer to https://

www.fda.gov/AboutFDA/WorkingatFDA

/BuildingsandFacilities/WhiteOak

CampusInformation/default.htm. 

You may submit comments as 

follows. Please note that late, untimely 

filed comments will not be considered. 

Electronic comments must be submitted 

on or before April 18, 2018. The https:// 

www.regulations.gov electronic filing 

system will accept comments until 

midnight Eastern Time at the end of 

April 18, 2018. Comments received by 

mail/hand delivery/courier (for written/ 

paper submissions) will be considered 

timely if they are postmarked or the 

delivery service acceptance receipt is on 

or before that date. 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 

Written/Paper Submissions 

Submit written/paper submissions as 

follows: 

• Mail/Hand delivery/Courier (for 

written/paper submissions): Dockets 

Management Staff (HFA–305), Food and 

Drug Administration, 5630 Fishers 

Lane, Rm. 1061, Rockville, MD 20852. 

• For written/paper comments 

submitted to the Dockets Management 

Staff, FDA will post your comment, as 

well as any attachments, except for 

information submitted, marked and 

identified, as confidential, if submitted 

as detailed in ‘‘Instructions.’’ 

Instructions: All submissions received 

must include the Docket No. FDA– 

2017–N–5568 for ‘‘Prescription Drug 

User Fee Act of 2017; Electronic 

Submissions and Data Standards.’’ 

Received comments, those filed in a 

timely manner (see ADDRESSES), will be 

placed in the docket and, except for 

those submitted as ‘‘Confidential 

Submissions,’’ publicly viewable at 

https://www.regulations.gov or at the 

Dockets Management Staff between 9 

a.m. and 4 p.m., Monday through 

Friday. 

• Confidential Submissions—To 

submit a comment with confidential 

information that you do not wish to be 

made publicly available, submit your 

comments only as a written/paper 

submission. You should submit two 

copies total. One copy will include the 

information you claim to be confidential 

with a heading or cover note that states 

‘‘THIS DOCUMENT CONTAINS 

CONFIDENTIAL INFORMATION.’’ The 

Agency will review this copy, including 

the claimed confidential information, in 

its consideration of comments. The 

second copy, which will have the 

claimed confidential information 

redacted/blacked out, will be available 

for public viewing and posted on 

https://www.regulations.gov. Submit 

both copies to the Dockets Management 

Staff. If you do not wish your name and 

contact information to be made publicly 

available, you can provide this 

information on the cover sheet and not 

in the body of your comments and you 

must identify this information as 

‘‘confidential.’’ Any information marked 

as ‘‘confidential’’ will not be disclosed 

except in accordance with 21 CFR 10.20 

and other applicable disclosure law. For 

more information about FDA’s posting 

of comments to public dockets, see 80 

FR 56469, September 18, 2015, or access 

the information at: https://www.gpo.gov

/fdsys/pkg/FR-2015-09-18/pdf/2015-233

89.pdf. 

Docket: For access to the docket to 

read background documents or the 

electronic and written/paper comments 

received, go to https://

www.regulations.gov and insert the 

docket number, found in brackets in the 

heading of this document, into the 

‘‘Search’’ box and follow the prompts 

and/or go to the Dockets Management 

Staff, 5630 Fishers Lane, Rm. 1061, 

Rockville, MD 20852. 

FOR FURTHER INFORMATION CONTACT: Ron 

Fitzmartin, Center for Drug Evaluation 


asabaliauskas on DSKBBXCHB2PROD with NOTICES